Iron deficiency anemia treatment anemia, Iron-Deficiency ferrous fumarate
Conditions
Interventions
Participants will receive ferrous fumarate 400 mg (two 200 mg tablets), taken orally on alternate days for 8
weeks. This dosing strategy is being evaluated for improved iron absorption and fewer gastr
Experimental Drug,Active Comparator Drug
Alternate-Day Dosing Group,Once-Daily Dosing Group
Sponsors
Division of Hematology, Department of Medicine, Phramongkutklao Hospital
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged 20 years or older diagnosed with iron deficiency anemia defined as hemoglobin less than 13 g/dL in males or less than 12 g/dL in females and ferritin less than 50 ng/mL or transferrin saturation less than 20 percent 2. No iron supplementation within the past 3 months
Exclusion criteria
Exclusion criteria: 1. Hemodynamic instability such as acute bleeding or hypotension 2. Severe heart failure classified as New York Heart Association Class III or IV or other active cardiac diseases 3. Active malignancy or history of cancer within the past 3 years except nonmelanoma skin cancer 4. Pregnancy or breastfeeding 5. Chronic liver disease including cirrhosis classified as Child-Pugh class B or C 6. Chronic kidney disease with estimated glomerular filtration rate less than 60 mL per minute per 1.73 square meters 7. Clinically significant thalassemia or hemoglobinopathies 8. Ongoing infection or chronic inflammatory diseases such as rheumatoid arthritis or inflammatory bowel disease 9. Malabsorption disorders including history of bariatric surgery 10. Red blood cell transfusion within the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin Level Week 4 and 8 Blood for complete blood count (CBC). Hemoglobin concentration measured at Week 4 and 8 following oral ferrous fumarate supplementation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reticulocyte Count Week 4 and 8 Blood for reticulocyte count. Change in Reticulocyte Count at Weeks 4 and 8,Serum Ferritin Week 4 and 8 Blood for serum ferritin. Change in Serum Ferritin at Weeks 4 and 8,Adverse Effects of Ferrous Fumarate During the 8-week treatment period Incidence and type of adverse effects experienced by participants during treatment with ferrous fumarate oral tablets. | — |
Countries
Thailand
Contacts
Public ContactTanapun Thamgrang
Phramongkutklao Hospital
Outcome results
None listed